cardiovascular outcomes

Impact of Digitalis Glycosides on Cardiovascular Outcomes in HFmrEF and HFrEF: A Comprehensive Evidence Synthesis

By MedXY 09/16/2026

Digitalis glycosides reduce cardiovascular death or worsening heart failure events in HFmrEF and HFrEF patients over a median of 36–37 months, supported by randomized trials and meta-analyses highlighting their role in select heart failure populations.

Cardiology news

Advancing Prognostic Precision in HFpEF: The LIFE-Preserved Risk Prediction Model

By MedXY 09/11/2026

The LIFE-Preserved model accurately predicts short-term and lifetime risks of heart failure hospitalization or cardiovascular death in HFpEF patients, enabling tailored clinical risk stratification and improved management.

Cardiology Clinical Updates Diabetes & Endocrinology news

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review

By MedXY 09/02/2026

GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophrenia. Semaglutide shows particular promise in improving cardiometabolic health.

Cardiology news

Refining Myocardial Infarction Diagnosis: A Novel Causal Endotype-Based Classification Beyond Type 1 and Type 2 MI

By MedXY 09/01/2026

This study introduces a causal endotype-based classification of myocardial infarction, revealing distinct underlying mechanisms and clinical outcomes beyond the traditional type 1/type 2 framework, potentially improving MI diagnosis and management.

Cardiology Clinical Updates news

Evaluating the Clinical and Health Outcomes of Financial Incentives in Hypertension Management: A Comprehensive Review

By MedXY 08/11/2026

This review synthesizes evidence on physician-focused financial incentives for hypertension control, highlighting nuanced impacts on clinical decisions, documented blood pressure control, and cardiovascular outcomes, with a focus on both overall and borderline hypertensive populations.

Cardiology Clinical Updates news

Elevated Endogenous Insulin and Insulin Resistance in Progressive Diastolic Dysfunction and Cardiovascular Risk: A Comprehensive Clinical Review

By MedXY 08/11/2026

Elevated endogenous insulin and insulin resistance independently predict progression of diastolic dysfunction and increased cardiovascular mortality, highlighting early metabolic dysregulation as a target to prevent heart failure with preserved ejection fraction.

Clinical Updates news

Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery

By MedXY 07/04/2026

Hypothyroidism increases the incidence of CABG and is linked to higher risks of postoperative complications, heart failure, stroke, and major adverse cardiovascular events, highlighting the importance of preoperative thyroid function optimization.

Cardiology news Respiratory

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value

By MedXY 07/03/2026

A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.

Cardiology Diabetes & Endocrinology news

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

By MedXY 06/10/2026

A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascular disease.

Cardiology news

Exploring the Impact of Body Mass Index on Heart Failure Outcomes: Insights from Mendelian Randomization

By MedXY 06/10/2026

This study leverages Mendelian randomization to demonstrate that genetically elevated BMI is associated with increased mortality and adverse cardiovascular outcomes in heart failure, irrespective of ejection fraction status, underscoring potential benefits of weight management.

Cardiology news

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study

By MedXY 06/10/2026

This study uses Mendelian randomization to show that higher genetically predicted BMI is associated with increased all-cause mortality and cardiovascular events in heart failure patients, regardless of ejection fraction status.

Cardiology news Respiratory

Cardiovascular Benefit of CPAP May Be Greater in High-Risk Obstructive Sleep Apnoea

By MedXY 05/15/2026

This pooled analysis found that CPAP may lower cardiovascular event risk mainly in patients with high-risk obstructive sleep apnoea, especially those with stronger heart-rate surges or greater oxygen deprivation during sleep.

Cardiology news

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy

By MedXY 05/10/2026

CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen's efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432 participants, it aims to establish a new treatment paradigm.

Cardiology Diabetes & Endocrinology news

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes

By MedXY 04/18/2026

A large-scale multinational study of over 1.2 million patients reveals that individual GLP-1 receptor agonists and SGLT2 inhibitors offer broadly similar cardiovascular protection in type 2 diabetes, challenging assumptions about meaningful differences between agents.

Clinical Updates Neurology news Rehabilitation Medicine

Integrated Strategies for Stroke Prevention and Management: From Evidence-Based Dietary Patterns to Systemic Adherence

By MedXY 04/08/2026

This review synthesizes recent evidence on the neuroprotective effects of healthy dietary patterns (Mediterranean, MIND), the synergistic impact of lifestyle and pharmacotherapy (GLP-1), and systemic advances in acute stroke care and secondary prevention.

Clinical Updates news

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY 03/25/2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major adverse cardiovascular events.

Cardiology Diabetes & Endocrinology news

Tirzepatide Outperforms Dulaglutide in Cardiovascular Risk Reduction: Insights from Real-World Target-Trial Emulations

By MedXY 03/11/2026

A large-scale target-trial emulation study reveals that tirzepatide significantly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality compared to dulaglutide in patients with type 2 diabetes and ASCVD, while performing similarly to semaglutide.

Diabetes & Endocrinology Nephrology news

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY 02/03/2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various stages of renal impairment.

Diabetes & Endocrinology Gastroenterology news

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD

By MedXY 01/07/2026

A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partially mediated by liver disease regression.

Cardiology Diabetes & Endocrinology news

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

By MedXY 01/04/2026

A large-scale retrospective study demonstrates that semaglutide reduces all-cause mortality by 46% in non-overweight patients with Type 2 diabetes compared to DPP-4 inhibitors, highlighting cardioprotective benefits independent of weight reduction.